Lion Biotechnologies to Present at Upcoming Investor Conferences in March

SAN CARLOS, CA -- (Marketwired) -- 02/27/17 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, announced today that company management will present a corporate update at two investor conferences in March:

• Cowen and Company 37th Annual Health Care Conference in Boston, MA on Monday, March 6, 2017 at 4:40 p.m. ET
• 29th Annual ROTH Conference in Orange County, CA on Monday, March 13, 2017 at 9:30 a.m. PT

Live webcasts of the presentations will be available by visiting the Investors section of Lion Biotechnologies' website at http://ir.lbio.com/. Replays of the webcasts will be archived on Lion Biotechnologies' website for 30 days following the presentations.

About Lion Biotechnologies, Inc.

Lion Biotechnologies, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The Company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocyte (TIL) technology for the treatment of patients with refractory metastatic melanoma. TIL therapy is also being evaluated in clinical trials at the National Cancer Institute and Moffitt Cancer Center. For more information, please visit http://www.lionbio.com.

   Investor Contact:Sarah McCabeStern Investor Relations, [email protected] Contact:Alex FerrarainVentivHealth Public [email protected] 

Source: Lion Biotechnologies, Inc.

You May Also Be Interested In

• Atlantic Street Capital Partners with GLP
• PlantArcBio's Yield Increasing and Drought-Tolerance Genes Deliver Stronger Yields in First Open-Field Corn Trial
• ESGold Intersects Multiple Sulphide-Bearing Intervals as Montauban Drilling Surpasses 2,000 Metres